Dementia and Alzheimer Disease

Neurology News Network for the week ending July 11, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.

New findings indicate that cognitive health in old age depends in part on cognitive development in early life.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

No differences were observed between the insulin and placebo groups on several clinical outcome measures as well as biomarker evaluations.

People with Down syndrome may be a suitable population for clinical trials for Alzheimer disease as prevalence ranges from 90% to 100% by the seventh decade of life.

In part 2 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.

Neurology News Network for the week ending June 27, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

In part 1 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center discussed how she adapted quickly to optimizing telemedicine for elderly patients with Alzheimer disease and cognitive decline.

Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease.

Compared to participants with ≤1 healthy lifestyle factor, the risk of developing Alzheimer disease was 37% lower in those with 2 or 3, and 60% lower in those with 4 or 5 healthy lifestyle factors.

The Women's Alzheimer's Prevention Center becomes the first medical clinic in the US to offer a women-specific center for Alzheimer disease prevention, research, and caregiving support.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

The drug, previously approved for Parkinson disease psychosis, received breakthrough therapy designation for this new indication.

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 12, 2020.

The founding executive director and chief science officer of the Alzheimer’s Drug Discovery Foundation discussed the recent approval of the imaging agent flortaucipir F18.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 5, 2020.

The GERA-US study assessed societal costs associated with MCI and mild dementia, and caring for someone with Alzheimer disease, and was the first such study to show how the early stages of cognitive decline economically impact both patients and their caregivers.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 29, 2020.